Peter Salzmann

Peter Salzmann, M.D., M.B.A. is the Chief Executive Officer of Immunovant and a member of Immunovant’s board of directors. From November 2018 to June 2019, he served as a Global Development Leader in Immunology at Eli Lilly and Company, where he was responsible for the design of a comprehensive indication strategy and Phase 2 and 3 clinical trial execution. From May 2013 to October 2018, Dr. Salzmann was Head of U.S. Immunology at Eli Lilly, and he also served as Managing Director of Lilly Alps from January 2011 to April 2013. From January 2008 to December 2010, Dr. Salzmann was the Head of Marketing for Eli Lilly China.

Dr. Salzmann earned a B.A. in Chemistry from Northwestern University, an M.D. from University of Chicago’s Pritzker School of Medicine, and an M.B.A. from Stanford University’s Graduate School of Business.